Übersetzung für "Hyperalgesia" in Deutsch

The peptide of claim 1, for use wherein the peripheral neuropathy causes hyperalgesia.

The peptide for use according to claim 1, for use wherein the chemotherapeutic agent causes hyperalgesia.

The peptide for use according to claim 1, wherein the chemotherapeutic agent causes hyperalgesia.

Hyperalgesia means increased sensitivity to pain.

In contrast, the specific cathepsin D inhibitors according to the invention were able to reduce the extent of thermal hyperalgesia as a function of the dose.

The hyperalgesia is quoted as the difference in the withdrawal times between the inflamed and non-inflamed paw.

The hyperalgesia is quoted as the difference in the withdrawal times between the inflamed and the non-inflamed paw.

Hyperalgesia denotes increased sensitivity for pain.

To study the effect of extremely low frequency magnetic field on hyperalgesia in mice.

If your doctor suspects Effentora-related increased sensitivity to pain (hyperalgesia), a reduction of your Effentora dose may be considered (see section 2 under “Warnings and precautions”).

As with other opioids, in case of insufficient pain control in response to an increased dose of fentanyl, the possibility of opioid-induced hyperalgesia should be considered.

In absence of adequate pain control, the possibility of hyperalgesia, tolerance and progression of underlying disease should be considered (see section 4.4).

Additionally, the two endocannabinoids significantly decreased neuropathic mechanical hyperalgesia (increased pain sensation) 7 days after damage to the sciatic nerve in animals.

According to research at the Virginia Commonwealth University in Richmond, USA, blockade of the enzyme fatty acid amide hydrolase (FAAH), which degrades the endocannabinoid anandamide, reduces development of arthritis and associated increased pain sensitivity (hyperalgesia) in mice.

A synthetic cannabinoid (JWH-133), which selectively activates the CB2 receptor decreased hyperalgesia, an increased sensitivity to pain, in a rat model of multiple sclerosis.

Typical characteristics of persistent pain are increased response to pain stimuli (hyperalgesia), painful perception of usually non-painful stimuli (allodynia) and the development of spontaneous pain without apparent cause.

In contrast to common stage-3 opioids, in animal models the compounds according to the invention exhibit a significant increase in efficacy for chronic inflammatory pain (carageenan- or CFA-induced hyperalgesia, visceral inflammatory pain, amongst others) compared to acute pain.

In contrast to common stage-3 opioids, side-effects typical of ?-opioids (respiratory depression, opioid-induced hyperalgesia, physical dependence/withdrawal, psychic dependence/addiction, among others) are significantly reduced or preferably not observed with the compounds according to the invention in the therapeutically effective dose range.

It has likewise surprisingly been found that the hydroxystatin derivatives according to the invention are able to reduce inflammation-induced thermal hyperalgesia depending on the dose.

The invention thus furthermore relates to a medicament comprising at least one compound according to the invention and/or one of its physiologically acceptable salts, derivatives, solvates, prodrugs and stereoisomers, including mixtures thereof in all ratios, for use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, selected from the group consisting of pain, allodynia and hyperalgesia.

The invention thus particularly preferably relates to a medicament comprising at least one compound according to the invention and/or one of its physiologically acceptable salts, derivatives, solvates, prodrugs and stereoisomers, including mixtures thereof in all ratios, for use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, selected from the group consisting of arthrosis, traumatic cartilage injuries, arthritis, pain, allodynia and hyperalgesia.